Language selection

Search

Patent 1179957 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent: (11) CA 1179957
(21) Application Number: 1179957
(54) English Title: PROCEDURE FOR THE EXTRACTION OF ANABOLIC, RESPIRATION- PROMOTING, LOW-MOLECULAR ACTIVE SUBSTANCES FOR PROPHYLACTIC, THERAPEUTIC, CELL-CULTURE AND TISSUE- CULTURE PURPOSES
(54) French Title: PROCEDE POUR L'EXTRACTION DE SUBSTANCES ACTIVES ANABOLIQUES, FAVORISANT LA RESPIRATION, DE FAIBLE POIDS MOLECULAIRE SERVANT A DES FINS PROPHYLACTIQUES ET THERAPEUTIQUES OU POURLA CULTURE DES TISSUS ET DES CELLULES
Status: Term Expired - Post Grant
Bibliographic Data
(51) International Patent Classification (IPC):
  • C12N 1/16 (2006.01)
  • C12N 1/06 (2006.01)
  • C12N 1/38 (2006.01)
  • C12P 1/02 (2006.01)
(72) Inventors :
  • JAEGER, KARL-HEINZ (Switzerland)
(73) Owners :
(71) Applicants :
(74) Agent: SMART & BIGGAR LP
(74) Associate agent:
(45) Issued: 1984-12-27
(22) Filed Date: 1982-05-14
Availability of licence: N/A
Dedicated to the Public: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): No

(30) Application Priority Data:
Application No. Country/Territory Date
3 131/81-9 (Switzerland) 1981-05-14

Abstracts

English Abstract


S u m m a r y
The procedure is intended to make it possible to
extract anabolic, respiration-promoting, low-molecular
active substances. The active substances can be used
for prophylactic, therapeutic and cell-culture and
tissue-culture purposes. The active substances are
obtained from a yeast plasmolysate, by the disintegrat-
ion of yeast fungi at the moment of their maximum
growth. The disintegration is achieved by the use of
ultrasound under the simultaneous influence of proteo-
lytic enzymes. The residue is subjected to dialysis
and very carefully concentrated.


Claims

Note: Claims are shown in the official language in which they were submitted.


THE EMBODIMENTS OE` THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. Procedure for the extraction of anabolic, respiration-promoting, low-
molecular active substances for prophylactic, therapeutic, cell-culture and
tissue-culture purposes, characterized by the disintegration of yeast fungi of
the Saccharomycetes family at the moment or their maximum growth by means of
ultrasound, in the presence of proteolytically active enzymes, the residue then
being subjected to dialysis and the dialysate concentrated under extremely
careful treatment.
2. Procedure according to claim 1, characterized by the use of papain
as a proteolytic enzyme.
3. Procedure according to claim 1 wherein the yeast fungi are fermented
at 25°C ? 3°C for 1 to 3 days, after which a proteolytic enzyme is added, the
mass of yeast fungi is spun by means of an ultrasound integrator of about 50
Watts/cm2 until the temperature of the yeast mass has risen to about 40°C, the
mass is then cooled, buffered to a pH value of 6.2 and centrifuged.

Description

Note: Descriptions are shown in the official language in which they were submitted.


1179957
Procedure for the extraction of anabolic, respiration-
promoting, low-molecular active substances for
prophylactic, therapeutic, cell-culture and tissue-
culture purposes
======================--===============================
This invention concerns a procedure for ~he extraction
of anabolic, respiration-promoting, low-molecular active
substances for prophylactic, therapeutic, cell-culture and
tissue-culture purposes.
It is known that yeast fungi of the Saccharomycetes
family have a high content of active substances such as
vitamins, enzymes and trace elements. To be mentioned
in particular are the riboflavins and their derivatives,
the vitamins of the B-complex, or the active substances
of the respiratory chain, such as cytochrome C, which are
extremely valuable for both humans and animals.
Apart from these known growth-promoting substances,
yeast fungi also contain growth factors, some unknown,
which can be described as true anabolics, such as are
contained, for example, in embryonal tissue and particularly
also in calf's blood, without which the growth of cells in
vitro would not take place.
It was interesting to observe that such chemically
still unidentified growth-promoting and respiration-
promoting factors from yeast fungi possess a great simil-
arity, from the functional point of view, to active sub-
stances from calf 15 serum, which is positively manifested
in the increased resistance of humans and animals against
bacterial, viral and other lesions.
Efforts were then made to find therapeutically usable
substances of this type in yeast plasmolysates, especially
such substances with a regenerative action on degradation
processes.

~ 3 ~ 11~9957
It was subsequently shown, however, that it was not
a simple matter to identify or isolate substances with
regenerative action from a yeast plasmolysate, since a
yeast plasmolysate contains a large number of substances
with the most widely different actions.
Regenerative processes are known to need a high level
of metabolic efficiency, which is linked with an increase
in the internal respiration. In order to detect the
desired substances with regenerative and respiration-
promoting properties from yeast plasmolysates, and also
to determine the most suitable production process for
the active principle, certain test procedures had to be
used, by means of which the presence and the concentration
of these substances could be demonstrated. Methods used
for tissue cultures in vitro proved particularly suitable
for this purpose.
Up till now it has not been possible to present the
desired substances from yeast cells in a chemically pure
form, since they are present in the yeast cell in only
very small concentrations.
Surprisingly, it could be estahlished that low-
molecular active substances with respiration-promoting
or metabolism-activating and regenerative properties
could be extracted from a yeast plasmolysate produced
by the process which is the subject of this invention.
In the non-denatured yeast cell these active sub-
stances can be detected either not at all or only with
difficulty, since they are present in bound or inactive
form and thus escape direct detection, so that they can
also not react therapeutically. After the discovery of
such active substances the task was to develop a process
enabling these substances from yeast cells to be separ-
ated from the high-molecular components of the cells,
concentrated and presented in a form usable in therapy.

~ 4 ~ 1179957
Tests have shown that the usual procedures, such as
freezing, salting out, heating, acid or alkaline plasmo-
lysis, trituration etc., of the yeast cells, do not
provide satisfactory results. The problem of how to
destroy the yeast-cell membrane as thoroughly as possible,
in order to obtain a high yield of active substance,
has not yet been satisfactorily solved.
Up till now no suitable method was known for the
purification of the extracted growth-promoting substances;
in particular, the procedures for deproteinization by
precipitation of the non-denatured proteins of the yeast
hyaloplasm by the usual methods, such as, for example,
by heating or by the use of trichloroacetic acid, were
not satisfactory, because with such precipitation of the
protein the substances one is trying to extract are also
precipitated out at the same time.
It has now been discovered that the most effective
disintegration of the yeast cells is obtained by adding
a sugar-containing solution, such as molasses, fruit-
juice waste and similar material, to a yeast mass, then
leaving this mass to ferment under adequate ventilation
at 25C + 3 C for 1 to 3 days, and after this adding a
proteolytic enzyme, such as papain for example, to the
resultant yeast-mass suspension. Then, at the moment
of optimum fermentation, the mass is spun by means of
an ultrasound integrator of 50 Watt~cm2 output until
the temperature of the yeast suspension has risen to
about 40C, which occurs with a residue of 70-75~.
The solution is then cooled, buffered to a pH value of
6.2 and centrifuged in portions. The residues of the
centrifugates are combined and then subjected to an end-
dialysis, which is carried out against neutral ~uffered
water. The whole is then carefully concentrated. In
order to preserve the producl obtained by this procedure
a well-known preservative agent is added.

~ 5 - 1179957
Surprisingly, it was observed that with the procedure
which is the subject of this invention the yield of
respiration-promoting active substances is three times
as great as with a normally applied papain proteolysis,
without the action of simultaneous ultrasound. This is
all the more surprising, since it could not be foreseen.
For better understanding of the procedure, the in-
vention is illustrated by the following practical example.
Practical examPle
100 litres of water containing about 5 kg of sugar-
containing raw materials are added to 1 kg of yeast
fungus, preferably a top-fermented or bottom-fermented
yeast strain of the species, Saccharomyces cerevisiae.
The whole mixture is left to stand for 1 to 3 days at
a temperature of about 25C, with good ventilation.
A proteolytic enzyme, preferably papain, is then added
in the proportion of 2-5~ of the total biomass. The
whole is then spun, by means of an ultrasound integrator
of 50 Watt~cm2 output until the temperature of the bio-
mass rises to 40C; the residue is then 70-75~. The
whole solution is then brought to a pH value of 6.2 and
centrifuged in portions. The centrifugates are combined
and subjected to an end-dialysis, which is carried out
at about 25-30C against neutral buffered water. Before
the start of the end-dialysis a preservatiYe agent is
added to the centrifugates, in a quantity sufficient to
ensure that at the end of the final dialysis the con-
centration of this agent in the dialysate is between
0.001 and 0.008%. As preservative agents, p-amino-
benzoic acid methylester and/or p-aminobenzoic acid
ethylester can be used to advantage.
It has been shown that this preservative lowers the
oxygen uptake of, for example, a liver homogenate or a
.

- 6 ~ 1~79957
yeast culture, by the active substance, by a maximum of
about 1~%, compared with the active substance without
any preservative agent. The end-dialysate is then care-
fully concentrated to 50 mg per ml of dialysate.
The end-product is standardized and tested by being
added, in a dilution of 1:100 to 1:10 000, to a normal
tissue culture, in vitro, with a cell-count being carried
out at the appropriate time. It has been shown that
compared with a control tissue culture without the
addition of active substance the cell-count increases
by at least 150%.
It is also possible to carry out standardization by
direct measurement of the acceleration of cell-division
of cells cultured in vitro, such as fibroblasts of
human or animal origin. The increased resistance through
administration of the active substances obtained ~y the
procedure which is the subject of this invention is
determined by adding toxic metallic salts, such as lead
or mercury compounds, to human or animal cells in such
a way that their mitotic capacity is impaired or blocked.
The degree of deblocking of this effect which is ob-
tained through the action of the growth-factors then
gives the degree of resistance.
Further investigations have shown that the end-product,
through stimulation of the metabolism, promotes oxygen
uptake and, at the same time, the increased production
of adenosine triphosphate. The end-product catalyses
and activates the respiratory chain at the leYel of the
cytochrome oxidase. For these reasons, in the case of
a wound for example, the active substance leads to in-
creased cell-division and thus to rapid epithelializ-
ation and healing. From calculations of feed utiliz-
ation in domestic animals it has been shown that the
addition of the active substance leads to better

~ 7 ~ 1179957
utilization of the basic feed so that these animals
also reach their desired degree of maturity much faster
than animals whose feed contains no active substance.
It has also been shown that a fermentation process,
for example, can be considerably activated by addition
of this active substance. It could thus be established
that the active substance can be used successfully in
the brewing of beer, in that a normal fermentation
process, which otherwise takes 8~2 days, for ~xample,
can be reduced to 7 days. The time-saving of 1~2 days
is of considerable importance fr~m the economic point
of view; in both cases the quality of the beer is the
same.
The growth factors produced by the procedure which
is the subject of this invention are not only suitable
for therapeutic use in human and veterinary medicine
but can also be used in the technical field of ferment-
ation processes, in the preparation of cell and tissue
cultures in vitro and for the improved utilization of
basic feed in animals.

Representative Drawing

Sorry, the representative drawing for patent document number 1179957 was not found.

Administrative Status

2024-08-01:As part of the Next Generation Patents (NGP) transition, the Canadian Patents Database (CPD) now contains a more detailed Event History, which replicates the Event Log of our new back-office solution.

Please note that "Inactive:" events refers to events no longer in use in our new back-office solution.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Event History , Maintenance Fee  and Payment History  should be consulted.

Event History

Description Date
Inactive: IPC expired 2016-01-01
Inactive: IPC deactivated 2011-07-26
Inactive: IPC from MCD 2006-03-11
Inactive: IPC from MCD 2006-03-11
Inactive: IPC from MCD 2006-03-11
Inactive: IPC from MCD 2006-03-11
Inactive: Expired (old Act Patent) latest possible expiry date 2002-05-14
Inactive: Reversal of expired status 2001-12-28
Inactive: Expired (old Act Patent) latest possible expiry date 2001-12-27
Grant by Issuance 1984-12-27

Abandonment History

There is no abandonment history.

Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
None
Past Owners on Record
KARL-HEINZ JAEGER
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column (Temporarily unavailable). To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Cover Page 1994-01-11 1 15
Claims 1994-01-11 1 22
Abstract 1994-01-11 1 9
Drawings 1994-01-11 1 5
Descriptions 1994-01-11 6 219